Valuation ORIC Pharmaceuticals, Inc. Börse Stuttgart
Stocks
4TZ
US68622P1093
Biotechnology & Medical Research
|
Market Closed -
Börse Stuttgart
12:47:12 2026-09-22 EDT
|
5-day change | 1st Jan Change | ||
| 11.30 EUR | +2.96% |
|
+1.39% | +59.06% |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 1,399 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 75.65% | - | - |
| Enterprise Value (EV) | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 1,399 | 1,399 | 1,399 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 86.33% | 0% | 0% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -8.88x | -8.07x | -7.29x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | -2.57x | -0.81x | -0.7x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 457x |
| EV / Revenue | - | - | - | - | - | - | - | 457x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -8.67x | -8.45x | -9.78x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -7.81x | -6.7x | -5.86x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -10.3x | -8.28x | -6.42x |
| FCF Yield | -10.4% | -29.2% | -17.2% | -20% | -14% | -9.72% | -12.1% | -15.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.521 | -1.672 | -1.852 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 3.064 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -161.4 | -165.6 | -143 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -179.1 | -209 | -238.7 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -166.6 | -200.1 | -239.6 |
| Net Debt | - | - | -235 | - | -45.67 | - | - | - |
| Reference price 2 | 14.70 | 5.89 | 9.20 | 8.07 | 8.18 | 13.50 | 13.50 | 13.50 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,653 | - | - |
| Announcement Date | 3/21/22 | 3/16/23 | 3/11/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.82x | 7.74x | 15.55x | 1.36% | 74.33B | |
| 32.35x | 9.35x | 29.12x | 0.04% | 62.26B | |
| 32.02x | 6.83x | 17.73x | -.--% | 27.72B | |
| -73.86x | 14.28x | -68.86x | -.--% | 26.42B | |
| -14.99x | 5.59x | -7.02x | -.--% | 24.62B | |
| 28.25x | 5.33x | 17.69x | -.--% | 20.72B | |
| 43.37x | 15.89x | 32.23x | 0.35% | 15.01B | |
| 17.67x | 5.26x | 12.29x | -.--% | 14.18B | |
| -14.6x | 3288.74x | -16.82x | -.--% | 13.48B | |
| Average | 8.00x | 373.22x | 3.54x | 0.19% | 30.97B | |
| Weighted average by Cap. | 12.53x | 167.26x | 8.13x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- 4TZ Stock
- Valuation ORIC Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
